Skip to main content
Signal8

PALATIN TECHNOLOGIES INC (PTN)

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Palatin Technologies, Inc. logo

Palatin Technologies, Inc.

NASDAQ:PTNHealthcare
AH-1.12%$5.30
Close$5.36-12.49%
Mkt Cap$9.55M
EV-
Float1.69M
O/S1.78M
VOL53K sh
$ Vol$295K
RVOL1.28×
Inst Own55.5%
SI17.4%
Net Cash/Sh-
Dilution
Palatin Technologies, Inc. logoNASDAQ:PTNAH$5.30-1.12%
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›